Silo Pharma Inc. (SILO) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SILO scores 18 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 0 / 20, reflecting ROIC of -35% and FCF yield of 0%. Whale 13F Flow scores 3 / 20 on institutional accumulation and options positioning. Insider Conviction scores 3 / 20 on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 7 / 20, with Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 5 / 20, reflecting Altman Z of 0.2, Piotroski F of 3/9, and Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the implication is that the rating's weakest pillars are the cash engine and the balance sheet, which are the two areas most directly tied to survival and dilution risk. The reported operating margin of -60% and the FY 2025 free cash flow of $-4.7M, set against cash of $4.7M, frame the central tradeoff: the company is consuming cash at roughly the pace of its reported balance. The modest positive pillar readings do not offset this. Upside drivers are not evidenced in the source data beyond the price's 52-week decline from $10.43 to $1.25, which is a valuation reset rather than a demonstrated improvement in fundamentals.

Per the market data, gross margin is 38.6%, while operating and net margins are both -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Reported net losses persisted across all three periods, and cash declined from $4.7M at FY 2025 to a level versus FY 2024's $3.9M that reflects a year-over-year increase rather than a decline. Debt is reported as N/A in each period.

Per the recent news section, six items reference SILO: a TradingView estimates report, a Yahoo Finance seasonal returns chart, a Benzinga pre-market movers list, a Simply Wall St stock analysis, and two TradingKey items (most active stocks and high dividend yield stocks). All are classified with a YELLOW light and MARKET WIRE impact label. The items are generic market-coverage pieces; none describes a specific fundamental event, product milestone, or financing. The Butterfly Supply-Chain Graph lists supply chain as NONE with no butterfly links and no proprietary signals. Risk watch items are therefore limited to the balance sheet, cash burn, and the 52-week price decline already noted above.

Per the Butterfly Supply-Chain Graph, supply chain is NONE and there are no butterfly links. Not available in source data for upstream dependencies, downstream customers, sector correlations, or 2nd-order bottlenecks.

• What specific products or drug candidates does Silo Pharma develop, and what is their clinical or regulatory stage?
• What is the company's revenue source given reported revenue of $0.1M against operating losses of roughly $4M per year?
• What is the current runway implied by cash of $4.7M against FY 2025 free cash flow of $-4.7M, and what financing options are disclosed?
• Why is debt reported as N/A across all periods, and what capital structure underlies the Debt/Equity of 0.5?
• What drove the 52-week decline from $10.43 to $1.25, and is any Nasdaq listing-compliance issue referenced in the sources?